BIXT Quote, Financials, Valuation and Earnings

MetaVia has a net margin of -- compared to Bioxytran's net margin of --. Bioxytran's return on equity of -- beat MetaVia's return on equity of --.

Bioxytran has a consensus price target of --, signalling downside risk potential of --. On the other hand MetaVia has an analysts' consensus of $14.33 which suggests that it could grow by 2027.55%. Given that MetaVia has higher upside potential than Bioxytran, analysts believe MetaVia is more attractive than Bioxytran.

Bioxytran has a beta of 1.555, which suggesting that the stock is 55.542% more volatile than S&P 500. In comparison MetaVia has a beta of 0.214, suggesting its less volatile than the S&P 500 by 78.621%.

Bioxytran has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MetaVia offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bioxytran pays -- of its earnings as a dividend. MetaVia pays out -- of its earnings as a dividend.

Bioxytran quarterly revenues are --, which are smaller than MetaVia quarterly revenues of --. Bioxytran's net income of -$1.4M is higher than MetaVia's net income of -$3.7M. Notably, Bioxytran's price-to-earnings ratio is -- while MetaVia's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bioxytran is 53.82x versus -- for MetaVia. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Bioxytran's net margin of -49.65%. Bioxytran's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Bioxytran has a consensus price target of --, signalling downside risk potential of --. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 31.62%. Given that NovaBay Pharmaceuticals has higher upside potential than Bioxytran, analysts believe NovaBay Pharmaceuticals is more attractive than Bioxytran.

Bioxytran has a beta of 1.555, which suggesting that the stock is 55.542% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

Bioxytran has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bioxytran pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Bioxytran quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Bioxytran's net income of -$1.4M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Bioxytran's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bioxytran is 53.82x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of -- compared to Bioxytran's net margin of --. Bioxytran's return on equity of -- beat Oragenics's return on equity of --.

Bioxytran has a consensus price target of --, signalling downside risk potential of --. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 2012.89%. Given that Oragenics has higher upside potential than Bioxytran, analysts believe Oragenics is more attractive than Bioxytran.

Bioxytran has a beta of 1.555, which suggesting that the stock is 55.542% more volatile than S&P 500. In comparison Oragenics has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.446%.

Bioxytran has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bioxytran pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

Bioxytran quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. Bioxytran's net income of -$1.4M is higher than Oragenics's net income of -$2.2M. Notably, Bioxytran's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bioxytran is 53.82x versus 0.45x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -- compared to Bioxytran's net margin of --. Bioxytran's return on equity of -- beat Theriva Biologics's return on equity of --.

Bioxytran has a consensus price target of --, signalling downside risk potential of --. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1402.15%. Given that Theriva Biologics has higher upside potential than Bioxytran, analysts believe Theriva Biologics is more attractive than Bioxytran.

Bioxytran has a beta of 1.555, which suggesting that the stock is 55.542% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.

Bioxytran has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bioxytran pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Bioxytran quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Bioxytran's net income of -$1.4M is higher than Theriva Biologics's net income of -$4.3M. Notably, Bioxytran's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bioxytran is 53.82x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.